|
Glaxo earmarks
Rs 18,000 cr for genomic research
Global pharma giant GlaxoSmithKline (GSK) has earmarked a
whopping sum of Rs 18,000 crores for developing genomic drug
targets in two major disease segments, viz., obesity and oncology.
Indo-Polish
biotech venture feared to come a cropper
THE bilateral agreement reached three months ago between
the govts of India and Poland to explore the biotechnological
approaches to herbal drug development is feared to come a
cropper, thanks to the paucity of funds and byzantine bureaucratic
delays.
Ethypharm to
set up R&D and mfg units
Ethypharm, Europe’s leading company specialising
in drug delivery systems, has identified India as one of the
strategic destination for development of novel drug delivery
systems.
|
|
